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Abstract 
Esophageal sclerosis is the most common visceral manifestation of systemic sclerosis, 
resulting in impaired esophageal clearance and retention of ingested food; in addition, 
co-existence of lung fibrosis with esophageal scleroderma is not uncommon. Both the 
progression of generalized connective tissue disorders and the damaging effect of chronic 
aspiration due to esophageal dysmotility appear to be involved in this procedure of 
interstitial fibrosis. Nifedipine is a widely prescribed calcium antagonist in a significant 
percentage of rheumatologic patients suffering from Raynaud syndrome, in order to inhibit 
peripheral vasospasm. Nevertheless, blocking calcium channels has proven to contribute to 
exacerbation of gastroesophageal reflux, which consequently can lead to chronic aspiration. 
We describe the case of severe exacerbation of interstitial lung disease in a 76-year-old 
female with esophageal sclerosis who was treated with oral nifedipine for Raynaud 
syndrome. 
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Introduction 
Gastrointestinal dysmotility is not uncommon in patients suffering from systemic 
sclerosis (scleroderma), with a reported incidence even up to 80% [1]. Although 
scleroderma may affect all parts of the gastrointestinal tract, esophagus stands for the 
most frequently invaded organ in cases of gastrointestinal involvement, with 
gastroesophageal reflux disease (GERD) being the most common consequence of 
esophageal sclerosis [2]. The main mechanisms through which GERD complicates 
esophageal sclerosis include impaired efficacy of peristalsis and clearance, reduction of 
the pressure of the lower esophageal sphincter (LES), high incidence of hiatal hernias 
due to the gradual shortening of the organ, and delay of gastric emptying [3]. 
Concerning lung fibrosis and scleroderma, their firm association is well established. 
Patients suffering from scleroderma are likely to develop interstitial lung disease, 
accompanied or not by gradual establishment of pulmonary hypertension. Considering 
the fact that the natural progress of scleroderma is based on the increased 
accumulation of collagen, which eventually leads to fibrosis, it seems reasonable to 
assume that in cases of generalized scleroderma invasion, there is a higher risk of 
developing interstitial lung disease as a consequence of a chronic vicious circle of 
inflammation and fibrosis [4]. 
The presence of GERD in scleroderma is a strong contributor to the exacerbation of 
pulmonary complications, mainly through subclinical microaspiration, which triggers 
bronchoconstriction and chronic inflammation, highlighting the necessity of aggressive 
acid-reducing medication support in patients with scleroderma [5]. In addition, these 
patients should avoid treatment with any drug that could enhance GERD development. 
Recent studies suggest that calcium channel blockers (CCBs), and particularly 
nifedipine, increase the risk of GERD by significantly reducing the tone of the LES, 
increasing esophageal exposure to gastric acid and reducing the amplitude and 
duration of esophageal peristalsis [6–8]. According to these findings, the administration 
of CCBs should be avoided, if possible, in patients with GERD. 
We report a very interesting case of non-specific interstitial pneumonia developing 
in a 76-year-old female suffering from esophageal sclerosis and interstitial lung disease, 
after a 6-month period of receiving oral nifedipine for treating Raynaud syndrome. Our 
case underlines for the first time the urgent need of considering the potential effect of 
CCBs as an exaggerator of interstitial lung disease in patients with sclerosis-derived 
GERD, through enhancing chronic aspiration due to progression of esophageal 
dysmotility. 
Case Report 
Our patient was a 76-year-old never-smoker female who presented to the emergency 
department complaining of shortness of breath and retrosternal discomfort, after a chocking 
episode which had awakened her during the night. Physical examination revealed limited thickness 
of the fingers, presence of ulcers in the oral cavity, palmar telangiectasias and slightly audible crackle 
sounds bilaterally in the lower respiratory fields. Her vital signs were as follows: blood pressure 
160/95 mm Hg, heart rate 110 bpm, temperature 37.3°C, respiration rate 20/min and SatO2 84%. 
Due to low SatO2 levels, arterial blood gas examination was performed, revealing PaO2 51 mm Hg, 
PCO2 50 mm Hg and pH 7.36. Chest X-ray and electrocardiogram did not reveal any significant  
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pathological findings. Blood tests at admission demonstrated leukocytosis (11,800/mm3), 
slight thrombocytosis (410,000/mm3), C-reactive protein levels of 3.8 mg/dl and serum lactic 
dehydrogenase of 412 IU/l. The rheumatological patient’s medical history included presence of 
Sjögren’s syndrome, rheumatoid arthritis and cutaneous sclerosis (with clinical regression under 
treatment) and GERD (under anti-secretory treatment). In addition, she reported that approximately 
6 months before she had been diagnosed with Raynaud syndrome and arterial hypertension and 
since then she had been receiving oral nifedipine (40 mg) daily. The patient mentioned that after 
the initiation of treatment with nifedipine, arterial hypertension was controlled and she did not 
experience any other Raynaud phenomenon crisis; nevertheless, she reported signs of gradual 
intolerance of physical exercise, productive cough episodes and chocking episodes particularly at 
night, along with exacerbation of GERD symptoms, despite receiving anti-secretory treatment with 
proton pump inhibitors. 
As developing aspiration pneumonia was suspected and since chest X-ray was of no diagnostic 
value, the patient underwent thoracic CT scanning, which revealed thickening of the esophageal wall, 
along with bolus retention, and slight intralobular reticular opacity with peripheral distribution in 
both lungs, with evident signs of chronic interstitial disease (fig. 1). Considering the patient’s history, 
physical examination, laboratory test results and imaging findings, the diagnosis of organizing 
non-specific interstitial pneumonia was made. 
The initial management of our patient in the emergency department consisted of aggressive 
administration of 50% O2, salbutamol, ipratropium and budesonide through a Venturi mask and 
intravenous administration of hydrocortisone and omeprazole. After 2 h, the patient’s clinical 
condition had improved, with a new SatO2 of 93% and regression of dyspnea. The patient was 
referred to the Department of Respiratory Medicine for further hospitalization and was discharged 
after 9 days in excellent clinical condition. It was decided that nifedipine treatment for Raynaud 
syndrome should be replaced with diltiazem, which has proven to affect less esophageal dysmotility 
and lower sphincter pressure, compared to other CCBs [9]. Moreover, the daily dose of anti-secretory 
therapy with omeprazole was doubled. Nearly 12 months after her admission to the emergency 
department, the patient has not experienced similar severe GERD symptoms or respiratory 
complications, with both arterial hypertension and Raynaud syndrome efficiently controlled. 
Discussion 
CCBs, which are considered to be the gold standard in confronting Raynaud 
syndrome, have proven to be associated with impaired esophageal motility by various 
studies, with nifedipine so far dominating the researchers’ interest. This adverse effect 
is mediated by the inhibition of calcium influx into the smooth muscle cells, which is 
essential for adequate contraction and thus maintenance of efficient pressure of the 
LES, in order to prevent gastroesophageal reflux [10]. Moreover, CCBs tend to increase 
esophageal exposure to gastric acid and to reduce the amplitude and duration of 
esophageal peristalsis [6–8], implying the existence of multiple effects of these drugs on 
esophageal motility. These findings are in total accordance with the outcomes of a large 
study by the National Ambulatory Medical Care Service in the United States, which 
suggested that over the 10-year period of the study, treatment with CCBs was an 
independent factor for GERD-related physician visits [11]. Consequently, it is evident 
that CCBs should be prescribed with extreme caution in patients with potentially 
life-threatening GERD, such as patients with systemic sclerosis, particularly in cases of 
pre-existing lung invasion of the disease, as chronic aspiration may lead to rapid 
progression of lung fibrosis. Regarding the possibly beneficial effect of oral CCBs in 
patients with lung fibrosis, it appears that only short-term positive vascular response 
can be expected, with these encouraging findings appearing to be limited in interstitial 
lung diseases that are mainly characterized by inflammation rather than fibrosis, such 
as in progressive lung sclerosis [12].  
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It is reasonable to assume that treating patients with esophageal dysmotility with 
CCBs, e.g. for hypertension or angina pectoris, may resemble a serious risk factor of 
further impairment of GERD and GERD-related diseases, such as chronic inflammation 
of the respiratory tract. In patients with esophageal sclerosis, this vicious circle of 
aspiration and lung inflammation, apart from further enhancing fibrosis, is associated 
with an increased probability of sleep apnea, another life-threatening condition, which 
is consistent with the feeling of chocking that awakened our patient during the night 
[13]. Also, the absence of long-term beneficial effect of CCBs in progressive lung fibrosis 
further highlights the importance of their cautious prescription in patients with 
esophageal dysmotility. On the other hand, it is suggested that not all CCBs have to the 
same extent the adverse effects described above; it appears that diltiazem affects less 
esophageal dysmotility and lower sphincter pressure, compared to other CCBs [9]. This 
last finding was the reason why in our case was decided not to abandon CCBs, as our 
patient had experienced severe Raynaud crises. Diltiazem was an attracting alternative, 
providing minimal damaging effect on GERD and the concomitant aspiration risk. 
Nevertheless, its administration was accompanied by doubling of the daily proton 
pump inhibitor dose. 
Up to now, there are no solid data that can shed light on this therapeutic challenge. 
So far, the skepticism regarding the use of CCBs in patients with esophageal sclerosis 
mainly focuses on investigating the consequences of their administration in esophagus 
function itself. Although the up-to-date findings are undoubtedly impressive, the final 
effect of CCBs on GERD-related disorders remains unknown. In our patient, treatment 
of Raynaud syndrome with nifedipine appeared to have triggered the progression of 
the underlying interstitial lung disease, which fortunately for our patient was not 
clinically silent. In the opposite scenario of subclinical progression of the interstitial 
lung disease, the patient might have developed irreversible respiratory failure or even 
fatal respiratory arrest due to sleep apnea. Consequently, further prospective studies 
should be conducted in order to assess the short- and long-term effects of CCBs in 
patients with scleroderma complicated by esophageal dysmotility, GERD and serious 
GERD-related conditions, such as interstitial lung disease.  
Conclusions 
CCBs have been proven to be associated with a higher risk of developing 
gastroesophageal reflux. We report a case of rapid progression of interstitial lung 
disease and exacerbation of gastroesophageal reflux symptoms in a 76-year-old 
non-smoker female with esophageal sclerosis, after a 6-month period of receiving oral 
nifedipine. The patient finally addressed the emergency department with symptoms of 
respiratory distress, which were attributed to organizing interstitial pneumonia. After 
9 days of hospitalization the patient was discharged in excellent clinical condition and 
nifedipine was switched to diltiazem, along with increasing the daily dose of 
anti-secretory therapy. Nearly 12 months later, the patient has not experienced 
similarly severe GERD symptoms or respiratory complications and seems to tolerate 
the new therapeutic approach well. Our case report highlights the necessity of further 
investigation of the long-term effects of CCBs in GERD-related complications, 
particularly those imposing a significant risk of mortality, such as in lung fibrosis in  
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patients with already impaired esophageal motility, like those suffering from systemic 
sclerosis. 
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Fig. 1. Thoracic CT imaging: Evident bolus retention in the lumen of the esophagus (short arrows), 
due to impaired esophageal peristalsis, and slight intralobular reticular opacity with peripheral 
distribution in both lungs, compatible with interstitial disease complicated by organizing 
non-specific interstitial pneumonia (long arrows). 
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